Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
REPL
Stock Latest News
Company Announcements
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference
4d ago
8K
REPL
Premium
Company Announcements
Replimune Group Reports Increased Losses Amid R&D Expansion
2M ago
REPL
Premium
Ratings
Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position
2M ago
REPL
Premium
The Fly
Replimune reports Q2 EPS (90c), consensus (79c)
2M ago
REPL
Premium
The Fly
Replimune upgraded to Market Perform from Underperform at BMO Capital
2M ago
REPL
Premium
Company Announcements
Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
3M ago
REPL
Premium
Company Announcements
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
3M ago
REPL
Premium
Company Announcements
Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
3M ago
REPL
Premium
Company Announcements
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
3M ago
REPL
Premium
Company Announcements
Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
3M ago
REPL
Premium
Company Announcements
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
3M ago
REPL
Premium
Company Announcements
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
3M ago
BMY
REPL
Premium
Ratings
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating
3M ago
REPL
Premium
The Fly
Replimune upgraded to Buy from Neutral at H.C. Wainwright
3M ago
REPL
Premium
The Fly
Genelux price target raised to $20 from $10 at Maxim
3M ago
GNLX
REPL
Premium
Ratings
Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
3M ago
REPL
Premium
The Fly
Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
3M ago
REPL
Premium
The Fly
Replimune upgraded to Overweight from Neutral at Piper Sandler
3M ago
REPL
Premium
Company Announcements
Replimune Group’s FDA Resubmission for RP1 Accepted
3M ago
8K
REPL
Premium
The Fly
Replimune upgraded to Neutral from Underweight at JPMorgan
3M ago
REPL
Premium
The Fly
Replimune upgraded to Neutral at JPMorgan after BLA resubmission accepted
3M ago
REPL
Premium
Market News
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
3M ago
WW
AMD
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
